London, ON – January 16, 2020 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the completion of their Phase IIa Venous Leg Ulcer trial and that all North American sites have been soft closed and global database lock is expected in early March 2020.
“Stiris has thoroughly enjoyed their collaboration on this global trial, it was wonderful seeing patients have improved healing of their leg ulcerations. We are excited to see the next steps with this treatment and look forward to future collaborations,” said Amanda Carrera, Vice President.
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.